[Primary nephrotic syndromes in children in Iran].
Bodaghi
E
E
Chamsa
A M
AM
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications; D006776:Hospitals, Pediatric; D006785:Hospitals, University; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007492:Iran / Q000453:epidemiology; D008297:Male; D009402:Nephrosis, Lipoid / Q000150:complications; D009404:Nephrotic Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D011159:Population Surveillance; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone